From the Journals

Gel Offers Relief for Axillary Sweating 

A pooled analysis of two phase 3 trials found that a once-daily topical anticholinergic gel significantly improved sweat reduction and symptom severity in patients with axillary hyperhidrosis, with a tolerable safety profile.

Share

A recent study published in the JAAD Journal demonstrates that a once-daily topical gel, sofpironium (12.45%), significantly alleviates symptoms of primary axillary hyperhidrosis. Conducted in the U.S. with 701 participants aged 9 and older, the phase 3 trials revealed that 84.6% of those using the gel saw at least a 1-point improvement on the Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax-7). The treatment was well-tolerated with mild to moderate adverse events, offering hope for those struggling with excessive sweating.

Original Source(s)

Gel Offers Relief for Axillary Sweating 

A pooled analysis of two phase 3 trials found that a once-daily topical anticholinergic gel significantly improved sweat reduction and symptom severity in patients with axillary hyperhidrosis, with a tolerable safety profile.

  • by Stanley Gajete

  • July 2, 2025

  • 3 min

Related Content

Rapid Itch Relief Seen with Nemolizumab

Researchers examined early itch and sleep outcomes with interleukin-31 pathway inhibition in atopic dermatitis and prurigo nodularis in phase 3 trial analyses.

First Death From Alaskapox Reported

Alaska health officials warned of the risk of Alaskapox in the wake of the first death from the disease in January 2024.

AAD and PA Consulting Partner on Next-Generation DataDerm Clinical Data Registry

The American Academy of Dermatology (AAD) announced a new partnership with PA Consulting to establish a next-generation, qualified clinical data registry.